{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T15:29:28Z","timestamp":1778858968264,"version":"3.51.4"},"reference-count":75,"publisher":"Bentham Science Publishers Ltd.","issue":"20","funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81974528"],"award-info":[{"award-number":["81974528"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82174035"],"award-info":[{"award-number":["82174035"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81773959"],"award-info":[{"award-number":["81773959"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003819","name":"Hubei Province Natural Science Foundation in China","doi-asserted-by":"publisher","award":["2021CFA015"],"award-info":[{"award-number":["2021CFA015"]}],"id":[{"id":"10.13039\/501100003819","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018570","name":"central government guides the special funds for the development of local science and technology","doi-asserted-by":"publisher","award":["2020ZYYD016"],"award-info":[{"award-number":["2020ZYYD016"]}],"id":[{"id":"10.13039\/501100018570","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010846","name":"Health Commission of Hubei Province scientific research project in China","doi-asserted-by":"publisher","award":["WJ2019H527"],"award-info":[{"award-number":["WJ2019H527"]}],"id":[{"id":"10.13039\/501100010846","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>EphA1 has been identified as an oncoprotein in various tumors, and is associated with the prognosis of a variety of tumors in recent years. EphA1 is considered a driver gene in tumor genomics. There are significant differences in EphA1 expression levels in different types of normal tissues and tumors, and even in different stages of tumor development, suggesting its functional diversity. Changes at the gene level in cell biology are often used as biological indicators of cancer, known as biomarkers, which can be used to provide diagnostic or prognostic information and are valuable for improving the detection, monitoring and treatment of tumors. However, few prognostic markers can selectively predict clinically significant tumors with poor prognosis. These malignancies are more likely to progress and lead to death, requiring more aggressive treatment. Currently available treatments for advanced cancer are often ineffective, and treatment options are mainly palliative. Therefore, early identification and treatment of those at risk of developing malignant tumors are crucial. Although pieces of evidence have shown the role of EphA1 in tumorigenesis and development, its specific mechanism is still unknown to a great extent.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>This review reveals the changes and roles of EphA1 in many tumors and cancers. The change of EphA1 expression can be used as a biological marker of cancer, which is valuable for improving tumor detection, monitoring and treatment, and can be applied to imaging. Studies have shown that structural modification of EphA1 could make it an effective new drug. EphA1 is unique in that it can be considered a prognostic marker in many tumors and is of important meaning for clinical diagnosis and operative treatment. At the same time, the study of the specific mechanism of EphA1 in tumors can provide a new way for targeted therapy.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>Relevant studies were retrieved and collected through the PubMed system. After determining EphA1\nas the research object, by analyzing research articles on EphA1 in the PubMed system in recent 10 years, we\nfound that EphA1 was closely connected with the occurrence and development of tumors and further determined\nthe references according to the influencing factors for review and analysis.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>EphA1 has been identified as a cancer protein in various tumors, such as hepatocellular carcinoma, nasopharyngeal\ncarcinoma, ovarian cancer, gastric cancer, colorectal cancer, clear cell renal cell carcinoma,\nesophageal squamous cell carcinoma, breast cancer, prostate cancer and uveal melanoma. EphA1 is abnormally\nexpressed in these tumor cells, which mainly plays a role in cancer progression, tumor angiogenesis, intestinal\nenvironmental stability, the lymph node system, nervous system diseases and gynecological diseases. In a narrow\nsense, EphA1 is especially effective in breast cancer in terms of gynecological diseases. However, the specific\nmechanism of EphA1 leading to the change of cancer cells in some tumors is not clear, which needs further\nresearch and exploration.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>RTK EphA1 can be used as a biomarker for tumor diagnosis (especially a prognostic marker), an\nindispensable therapeutic target for new anti-tumor therapies, and a novel anti-tumor drug.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0929867329666220820125638","type":"journal-article","created":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T04:38:00Z","timestamp":1661229480000},"page":"2340-2353","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["The Functions of EphA1 Receptor Tyrosine Kinase in Several Tumors"],"prefix":"10.2174","volume":"30","author":[{"given":"Yinxin","family":"Wu","sequence":"first","affiliation":[{"name":"Third-Grade Pharmacological Laboratory on Traditional Chinese Medicine, State Administration of Traditional Chinese Medicine, China\nThree Gorges University, Yichang 443002, P.R. China"},{"name":"College of Basic Medical Science, China Three Gorges University, Yichang\n443002, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuoying","family":"Du","sequence":"additional","affiliation":[{"name":"Third-Grade Pharmacological Laboratory on Traditional Chinese Medicine, State Administration of Traditional Chinese Medicine, China\nThree Gorges University, Yichang 443002, P.R. China"},{"name":"College of Basic Medical Science, China Three Gorges University, Yichang\n443002, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Mou","sequence":"additional","affiliation":[{"name":"Third-Grade Pharmacological Laboratory on Traditional Chinese Medicine, State Administration of Traditional Chinese Medicine, China\nThree Gorges University, Yichang 443002, P.R. China"},{"name":"College of Basic Medical Science, China Three Gorges University, Yichang\n443002, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyan","family":"Qiu","sequence":"additional","affiliation":[{"name":"Third-Grade Pharmacological Laboratory on Traditional Chinese Medicine, State Administration of Traditional Chinese Medicine, China\nThree Gorges University, Yichang 443002, P.R. China"},{"name":"College of Basic Medical Science, China Three Gorges University, Yichang\n443002, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinlan","family":"Chen","sequence":"additional","affiliation":[{"name":"Third-Grade Pharmacological Laboratory on Traditional Chinese Medicine, State Administration of Traditional Chinese Medicine, China\nThree Gorges University, Yichang 443002, P.R. China"},{"name":"College of Basic Medical Science, China Three Gorges University, Yichang\n443002, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjin","family":"Cai","sequence":"additional","affiliation":[{"name":"College of Basic Medical Science, China Three Gorges University, Yichang\n443002, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongming","family":"Ren","sequence":"additional","affiliation":[{"name":"College of Basic Medical Science, China Three Gorges University, Yichang\n443002, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fangxiang","family":"Xiao","sequence":"additional","affiliation":[{"name":"College of Basic Medical Science, China Three Gorges University, Yichang\n443002, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gang","family":"Zhou","sequence":"additional","affiliation":[{"name":"College of Traditional Chinese Medicine, China Three Gorges University, Yichang, 443002, P.R. China"},{"name":"Yichang\nHospital of Traditional Chinese Medicine, Yichang, 443002, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1894-0960","authenticated-orcid":true,"given":"Chengfu","family":"Yuan","sequence":"additional","affiliation":[{"name":"Third-Grade Pharmacological Laboratory on Traditional Chinese Medicine, State Administration of Traditional Chinese Medicine, China\nThree Gorges University, Yichang 443002, P.R. China"},{"name":"College of Basic Medical Science, China Three Gorges University, Yichang\n443002, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"102","DOI":"10.4161\/cam.19620","volume":"6","author":"Noberini R.","year":"2012","unstructured":"Noberini R.; Rubio de la Torre E.; Pasquale E.B.; Profiling Eph receptor expression in cells and tissues. Cell Adhes Migr 2012,6(2),102-156","journal-title":"Cell Adhes Migr"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1006\/mcpr.1999.0228","volume":"13","author":"Owshalimpur D.","year":"1999","unstructured":"Owshalimpur D.; Kelley M.J.; Genomic structure of the EPHA1 receptor tyrosinekinase gene. Mol Cell Probes 1999,13(3),169-173","journal-title":"Mol Cell Probes"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1126\/science.2825356","volume":"238","author":"Hirai H.","year":"1987","unstructured":"Hirai H.; Maru Y.; Hagiwara K.; Nishida J.; Takaku F.; A novel putative tyrosine kinase receptor encoded by the eph gene. Science 1987,238(4834),1717-1720","journal-title":"Science"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1093\/biolre\/ioaa171","volume":"104","author":"Adu-Gyamfi E.A.","year":"2021","unstructured":"Adu-Gyamfi E.A.; Czika A.; Liu T.H.; Gorleku P.N.; Fondjo L.A.; Djankpa F.T.; Ding Y.B.; Wang Y.X.; Ephrin and Eph receptor signaling in female reproductive physiology and pathology. Biol Reprod 2021,104(1),71-82","journal-title":"Biol Reprod"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1111\/cas.13942","volume":"110","author":"Ieguchi K.","year":"2019","unstructured":"Ieguchi K.; Maru Y.; Roles of EphA1\/A2 and ephrin-A1 in cancer. Cancer Sci 2019,110(3),841-848","journal-title":"Cancer Sci"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S0092-8674(00)81436-1","volume":"93","author":"Wang H.U.","year":"1998","unstructured":"Wang H.U.; Chen Z.F.; Anderson D.J.; Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4. Cell 1998,93(5),741-753","journal-title":"Cell"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1161\/01.ATV.0000055440.89758.C2","volume":"23","author":"Hamada K.","year":"2003","unstructured":"Hamada K.; Oike Y.; Ito Y.; Maekawa H.; Miyata K.; Shimomura T.; Suda T.; Distinct roles of ephrin-B2 forward and EphB4 reverse signaling in endothelial cells. Arterioscler Thromb Vasc Biol 2003,23(2),190-197","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13046-016-0339-6","volume":"35","author":"Wang Y.","year":"2016","unstructured":"Wang Y.; Yu H.; Shan Y.; Tao C.; Wu F.; Yu Z.; Guo P.; Huang J.; Li J.; Zhu Q.; Yu F.; Song Q.; Shi H.; Zhou M.; Chen G.; EphA1 activation promotes the homing of endothelial progenitor cells to hepatocellular carcinoma for tumor neovascularization through the SDF-1\/CXCR4 signaling pathway. J Exp Clin Cancer Res 2016,35(1),65","journal-title":"J Exp Clin Cancer Res"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1038\/s41598-018-19788-y","volume":"8","author":"Chu M.","year":"2018","unstructured":"Chu M.; Zhang C.; Inhibition of angiogenesis by leflunomide via targeting the soluble ephrin-A1\/EphA2 system in bladder cancer. Sci Rep 2018,8(1),1539","journal-title":"Sci Rep"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"225","DOI":"10.3390\/life10100225","volume":"10","author":"Gajdzis M.","year":"2020","unstructured":"Gajdzis M.; Theocharis S.; Gajdzis P.; Cassoux N.; Gardrat S.; Donizy P.; Klijanienko J.; Kaczmarek R.; Ephrin Receptors (Eph): EphA1, EphA5, and EphA7 expression in uveal melanoma\u2014associations with clinical parameters and patient survival. Life (Basel) 2020,10(10),225","journal-title":"Life (Basel)"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"3125","DOI":"10.1101\/gad.13.23.3125","volume":"13","author":"Davy A.","year":"1999","unstructured":"Davy A.; Gale N.W.; Murray E.W.; Klinghoffer R.A.; Soriano P.; Feuerstein C.; Robbins S.M.; Compartmentalized signaling by GPI-anchored ephrin-A5 requires the Fyn tyrosine kinase to regulate cellular adhesion. Genes Dev 1999,13(23),3125-3135","journal-title":"Genes Dev"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.cell.2014.02.013","volume":"157","author":"Scadden D.T.","year":"2014","unstructured":"Scadden D.T.; Nice neighborhood: Emerging concepts of the stem cell niche. Cell 2014,157(1),41-50","journal-title":"Cell"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"794","DOI":"10.4149\/neo_2020_190807N724","volume":"67","author":"Dai B.","year":"2020","unstructured":"Dai B.; Zhang X.; SOCS2 affects the proliferation, migration, and invasion of nasopharyngeal carcinoma cells via regulating EphA1. Neoplasma 2020,67(4),794-801","journal-title":"Neoplasma"},{"key":"ref=14","first-page":"4415","volume":"37","author":"Cui Y.","year":"2017","unstructured":"Cui Y.; Wu B.O.; Flamini V.; Evans B.A.J.; Zhou D.; Jiang W.G.; Knockdown of EPHA1 Using CRISPR\/CAS9 suppresses aggressive properties of ovarian cancer cells. Anticancer Res 2017,37(8),4415-4424","journal-title":"Anticancer Res"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"e923409","DOI":"10.12659\/MSM.923409","volume":"26","author":"Wang Y.C.","year":"2020","unstructured":"Wang Y.C.; Dai Y.; Xu G.L.; Yu W.; Quan R.L.; Zhao Y.J.; Association between EphA1 and tumor microenvironment in gastric carcinoma and its clinical significance. Med Sci Monit 2020,26,e923409","journal-title":"Med Sci Monit"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41417-020-00220-5","volume":"28","author":"Li P.","year":"2021","unstructured":"Li P.; Wang L.; Li P.; Hu F.; Cao Y.; Tang D.; Ye G.; Li H.; Wang D.; Silencing of long non-coding RNA XIST represses gastric cancer progression through blocking NF\u03baB pathway via inhibiting HNF4A-mediated transcription of EPHA1. Cancer Gene Ther 2021,28(3-4),307-320","journal-title":"Cancer Gene Ther"},{"key":"ref=17","first-page":"1211","volume":"36","author":"Wu B.O.","year":"2016","unstructured":"Wu B.O.; Jiang W.G.; Zhou D.; Cui Y.X.; Knockdown of EPHA1 by CRISPR\/CAS9 promotes adhesion and motility of HRT18 colorectal carcinoma cells. Anticancer Res 2016,36(3),1211-1219","journal-title":"Anticancer Res"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"e102262","DOI":"10.1371\/journal.pone.0102262","volume":"9","author":"Toma M.I.","year":"2014","unstructured":"Toma M.I.; Erdmann K.; Diezel M.; Meinhardt M.; Zastrow S.; Fuessel S.; Wirth M.P.; Baretton G.B.; Lack of ephrin receptor A1 is a favorable independent prognostic factor in clear cell renal cell carcinoma. PLoS One 2014,9(7),e102262","journal-title":"PLoS One"},{"key":"ref=19","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1600-0463.2012.02941.x","volume":"121","author":"Wang J.","year":"2013","unstructured":"Wang J.; Ma J.; Dong Y.; Shen Z.; Ma H.; Wang X.; Shi S.; Wu J.; Lu G.; Peng L.; Zhoud X.; High expression of EphA1 in esophageal squamous cell carcinoma is associated with lymph node metastasis and advanced disease. APMIS 2013,121(1),30-37","journal-title":"APMIS"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2021\/5575704","volume":"2021","author":"Liang Z.","year":"2021","unstructured":"Liang Z.; Wang X.; Dong K.; Li X.; Qin C.; Zhou H.; Expression pattern and prognostic value of EPHA\/EFNA in breast cancer by bioinformatics analysis: Revealing its importance in chemotherapy. BioMed Res Int 2021,2021,1-20","journal-title":"BioMed Res Int"},{"key":"ref=21","first-page":"1854","volume":"6","author":"Peng L.","year":"2013","unstructured":"Peng L.; Wang H.; Dong Y.; Ma J.; Wen J.; Wu J.; Wang X.; Zhou X.; Wang J.; Increased expression of EphA1 protein in prostate cancers correlates with high Gleason score. Int J Clin Exp Pathol 2013,6(9),1854-1860","journal-title":"Int J Clin Exp Pathol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1038\/s41598-019-38878-z","volume":"9","author":"Yu L.","year":"2019","unstructured":"Yu L.; Ke J.; Du X.; Yu Z.; Gao D.; Genetic characterization of thymoma. Sci Rep 2019,9(1),2369","journal-title":"Sci Rep"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s12253-013-9692-3","volume":"20","author":"Theocharis S.","year":"2014","unstructured":"Theocharis S.; Klijanienko J.; Giaginis C.; Alexandrou P.; Patsouris E.; Sastre-Garau X.; Ephrin receptor (Eph) -A1, -A2, -A4 and -A7 expression in mobile tongue squamous cell carcinoma: Associations with clinicopathological parameters and patients survival. Pathol Oncol Res 2014,20(2),277-284","journal-title":"Pathol Oncol Res"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"E359","DOI":"10.1002\/ijc.29210","volume":"136","author":"Ferlay J.","year":"2015","unstructured":"Ferlay J.; Soerjomataram I.; Dikshit R.; Eser S.; Mathers C.; Rebelo M.; Parkin D.M.; Forman D.; Bray F.; Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015,136(5),E359-E386","journal-title":"Int J Cancer"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1002\/cam4.4468","volume":"11","author":"Liu J.K.H.","year":"2022","unstructured":"Liu J.K.H.; Irvine A.F.; Jones R.L.; Samson A.; Immunotherapies for hepatocellular carcinoma. Cancer Med 2022,11(3),571-591","journal-title":"Cancer Med"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/nrd2115","volume":"6","author":"Folkman J.","year":"2007","unstructured":"Folkman J.; Angiogenesis: An organizing principle for drug discovery? Nat Rev Drug Discov 2007,6(4),273-286","journal-title":"Nat Rev Drug Discov"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"16588","DOI":"10.18632\/oncotarget.3752","volume":"6","author":"Nguyen M.P.","year":"2015","unstructured":"Nguyen M.P.; Lee D.; Lee S.H.; Lee H.E.; Lee H.Y.; Lee Y.M.; Deguelin inhibits vasculogenic function of endothelial progenitor cells in tumor progression and metastasis via suppression of focal adhesion. Oncotarget 2015,6(18),16588-16600","journal-title":"Oncotarget"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1002\/stem.583","volume":"29","author":"Melero-Martin J.M.","year":"2011","unstructured":"Melero-Martin J.M.; Dudley A.C.; Concise review: Vascular stem cells and tumor angiogenesis. Stem Cells 2011,29(2),163-168","journal-title":"Stem Cells"},{"key":"ref=29","first-page":"563","volume":"23","author":"Chen G.","year":"2010","unstructured":"Chen G.; Wang Y.; Zhou M.; Shi H.; Yu Z.; Zhu Y.; Yu F.; EphA1 receptor silencing by small interfering RNA has antiangiogenic and antitumor efficacy in hepatocellular carcinoma. Oncol Rep 2010,23(2),563-570","journal-title":"Oncol Rep"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1002\/hep.26790","volume":"59","author":"Chen Y.","year":"2014","unstructured":"Chen Y.; Huang Y.; Reiberger T.; Duyverman A.M.; Huang P.; Samuel R.; Hiddingh L.; Roberge S.; Koppel C.; Lauwers G.Y.; Zhu A.X.; Jain R.K.; Duda D.G.; Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha\/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice. Hepatology 2014,59(4),1435-1447","journal-title":"Hepatology"},{"key":"ref=31","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s12094-017-1777-0","volume":"20","author":"Pastor M.","year":"2018","unstructured":"Pastor M.; Lopez Pousa A.; Del Barco E.; Perez Segura P.; Astorga B.G.; Castelo B.; Bonfill T.; Martinez Trufero J.; Grau J.J.; Mesia R.; SEOM clinical guideline in nasopharynx cancer. Clin Transl Oncol 2018,20(1),84-88","journal-title":"Clin Transl Oncol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"e0229272","DOI":"10.1371\/journal.pone.0229272","volume":"15","author":"Ma F.","year":"2020","unstructured":"Ma F.; Gu X.; Liu J.Q.; Mo L.H.; Yang G.; Geng X.R.; Liu Z.Q.; Liu Z.G.; Yang P.C.; Inhibition of livin overcomes radioresistance in nasopharyngeal carcinoma cells. PLoS One 2020,15(3),e0229272","journal-title":"PLoS One"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"1533033818809993","DOI":"10.1177\/1533033818809993","volume":"17","author":"He H.","year":"2018","unstructured":"He H.; Liao X.; Yang Q.; Liu Y.; Peng Y.; Zhong H.; Yang J.; Zhang H.; Yu Z.; Zuo Y.; Guan C.; Xu Z.; MicroRNA-494-3p promotes cell growth, migration, and invasion of nasopharyngeal carcinoma by targeting Sox7. Technol Cancer Res Treat 2018,17,1533033818809993","journal-title":"Technol Cancer Res Treat"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","volume":"71","author":"Siegel R.L.","year":"2021","unstructured":"Siegel R.L.; Miller K.D.; Fuchs H.E.; Jemal A.; Cancer statistics, 2021. CA Cancer J Clin 2021,71(1),7-33","journal-title":"CA Cancer J Clin"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.ygyno.2014.06.030","volume":"135","author":"Fan L.","year":"2014","unstructured":"Fan L.; Chen J.; Zhang X.; Liu Y.; Xu C.; Follicle-stimulating hormone polypeptide modified nanoparticle drug delivery system in the treatment of lymphatic metastasis during ovarian carcinoma therapy. Gynecol Oncol 2014,135(1),125-132","journal-title":"Gynecol Oncol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13046-018-0700-z","volume":"37","author":"Yao S.","year":"2018","unstructured":"Yao S.; Li L.; Su X.; Wang K.; Lu Z.; Yuan C.; Feng J.; Yan S.; Kong B.; Song K.; Development and evaluation of novel tumor-targeting paclitaxel-loaded nano-carriers for ovarian cancer treatment: In vitro and in vivo. J Exp Clin Cancer Res 2018,37(1),29","journal-title":"J Exp Clin Cancer Res"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1016\/j.cub.2006.04.044","volume":"16","author":"Yamamoto T.","year":"2006","unstructured":"Yamamoto T.; Ebisuya M.; Ashida F.; Okamoto K.; Yonehara S.; Nishida E.; Continuous ERK activation downregulates antiproliferative genes throughout G1 phase to allow cell-cycle progression. Curr Biol 2006,16(12),1171-1182","journal-title":"Curr Biol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1016\/j.bbamcr.2006.11.010","volume":"1773","author":"Chambard J.C.","year":"2007","unstructured":"Chambard J.C.; Lefloch R.; Pouyss\u00e9gur J.; Lenormand P.; ERK implication in cell cycle regulation. Biochim Biophys Acta Mol Cell Res 2007,1773(8),1299-1310","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1158\/0008-5472.CAN-15-2906","volume":"77","author":"Jung M.","year":"2017","unstructured":"Jung M.; Russell A.J.; Liu B.; George J.; Liu P.Y.; Liu T.; DeFazio A.; Bowtell D.D.L.; Oberthuer A.; London W.B.; Fletcher J.I.; Haber M.; Norris M.D.; Henderson M.J.; A Myc activity signature predicts poor clinical outcomes in Myc-associated cancers. Cancer Res 2017,77(4),971-981","journal-title":"Cancer Res"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1002\/cam4.2055","volume":"8","author":"Wu D.","year":"2019","unstructured":"Wu D.; Zhang P.; Ma J.; Xu J.; Yang L.; Xu W.; Que H.; Chen M.; Xu H.; Serum biomarker panels for the diagnosis of gastric cancer. Cancer Med 2019,8(4),1576-1583","journal-title":"Cancer Med"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"1010428317714626","DOI":"10.1177\/1010428317714626","volume":"39","author":"Song Z.","year":"2017","unstructured":"Song Z.; Wu Y.; Yang J.; Yang D.; Fang X.; Progress in the treatment of advanced gastric cancer. Tumour Biol 2017,39(7),1010428317714626","journal-title":"Tumour Biol"},{"key":"ref=42","first-page":"1685","volume":"38","author":"Inokuchi M.","year":"2018","unstructured":"Inokuchi M.; Nakagawa M.; Baogok N.; Takagi Y.; Tanioka T.; Gokita K.; Okuno K.; Kojima K.; Prognostic significance of High EphA1-4 expression levels in locally advanced gastric cancer. Anticancer Res 2018,38(3),1685-1693","journal-title":"Anticancer Res"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1245\/s10434-014-4231-3","volume":"22","author":"Nakagawa M.","year":"2015","unstructured":"Nakagawa M.; Inokuchi M.; Takagi Y.; Kato K.; Sugita H.; Otsuki S.; Kojima K.; Uetake H.; Sugihara K.; Erythropoietin-producing hepatocellular A1 is an independent prognostic factor for gastric cancer. Ann Surg Oncol 2015,22(7),2329-2335","journal-title":"Ann Surg Oncol"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"3583","DOI":"10.3748\/wjg.v24.i32.3583","volume":"24","author":"Laz\u0103r D.C.","year":"2018","unstructured":"Laz\u0103r D.C.; Avram M.F.; Romo\u0219an I.; Cornianu M.; T\u0103ban S.; Goldi\u0219 A.; Prognostic significance of tumor immune microenvironment and immunotherapy: Novel insights and future perspectives in gastric cancer. World J Gastroenterol 2018,24(32),3583-3616","journal-title":"World J Gastroenterol"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2014\/149185","volume":"2014","author":"Landskron G.","year":"2014","unstructured":"Landskron G.; De la Fuente M.; Thuwajit P.; Thuwajit C.; Hermoso M.A.; Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res 2014,2014,1-19","journal-title":"J Immunol Res"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1615\/CritRevOncog.2017020557","volume":"22","author":"Zhou X.","year":"2017","unstructured":"Zhou X.; Tu P.; Chen X.; Guo S.; Wang J.; Eph receptors: Actors in tumor microenvironment. Crit Rev Oncog 2017,22(5-6),499-505","journal-title":"Crit Rev Oncog"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"2787","DOI":"10.1002\/jcb.26447","volume":"119","author":"Zhang Q.","year":"2018","unstructured":"Zhang Q.; Chen B.; Liu P.; Yang J.; XIST promotes gastric cancer (GC) progression through TGF\u2010\u03b21 via targeting miR\u2010185. J Cell Biochem 2018,119(3),2787-2796","journal-title":"J Cell Biochem"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"26144","DOI":"10.18632\/oncotarget.25456","volume":"9","author":"Taniguchi H.","year":"2018","unstructured":"Taniguchi H.; Fujimoto A.; Kono H.; Furuta M.; Fujita M.; Nakagawa H.; Loss-of-function mutations in Zn-finger DNA-binding domain of HNF4A cause aberrant transcriptional regulation in liver cancer. Oncotarget 2018,9(40),26144-26156","journal-title":"Oncotarget"},{"key":"ref=49","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1007\/s12094-017-1774-3","volume":"20","author":"Yang C.","year":"2018","unstructured":"Yang C.; Zhang J.; Ding M.; Xu K.; Li L.; Mao L.; Zheng J.; Ki67 targeted strategies for cancer therapy. Clin Transl Oncol 2018,20(5),570-575","journal-title":"Clin Transl Oncol"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s11010-018-3417-6","volume":"452","author":"Majumder A.","year":"2019","unstructured":"Majumder A.; Ray S.; Banerji A.; Epidermal growth factor receptor-mediated regulation of matrix metalloproteinase-2 and matrix metalloproteinase-9 in MCF-7 breast cancer cells. Mol Cell Biochem 2019,452(1-2),111-121","journal-title":"Mol Cell Biochem"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"5075","DOI":"10.1021\/acsnano.0c01676","volume":"14","author":"Guo J.","year":"2020","unstructured":"Guo J.; Yu Z.; Das M.; Huang L.; Nano codelivery of oxaliplatin and folinic acid achieves synergistic chemo-immunotherapy with 5-fluorouracil for colorectal cancer and liver metastasis. ACS Nano 2020,14(4),5075-5089","journal-title":"ACS Nano"},{"key":"ref=52","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.ejca.2011.07.003","volume":"48","author":"Herath N.I.","year":"2012","unstructured":"Herath N.I.; Spanevello M.D.; Doecke J.D.; Smith F.M.; Pouponnot C.; Boyd A.W.; Complex expression patterns of Eph receptor tyrosine kinases and their ephrin ligands in colorectal carcinogenesis. Eur J Cancer 2012,48(5),753-62","journal-title":"Eur J Cancer"},{"key":"ref=53","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/modpathol.2008.188","volume":"22","author":"Dong Y.","year":"2009","unstructured":"Dong Y.; Wang J.; Sheng Z.; Li G.; Ma H.; Wang X.; Zhang R.; Lu G.; Hu Q.; Sugimura H.; Zhou X.; Downregulation of EphA1 in colorectal carcinomas correlates with invasion and metastasis. Modern Pathol 2009,22(1),151-160","journal-title":"Modern Pathol"},{"key":"ref=54","first-page":"6821","volume":"8","author":"Wang X.","year":"2015","unstructured":"Wang X.; Liu Y.; Cao G.; Zhang X.; Xu H.; Xu H.; Wang J.; Expression of the EphA1 protein is associated with Fuhrman nuclear grade in clear cell renal cell carcinomas. Int J Clin Exp Pathol 2015,8(6),6821-6827","journal-title":"Int J Clin Exp Pathol"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/S1470-2045(09)70240-2","volume":"10","author":"Rini B.I.","year":"2009","unstructured":"Rini B.I.; Atkins M.B.; Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol 2009,10(10),992-1000","journal-title":"Lancet Oncol"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1093\/jjco\/hyz034","volume":"49","author":"Hirano H.","year":"2019","unstructured":"Hirano H.; Kato K.; Systemic treatment of advanced esophageal squamous cell carcinoma: chemotherapy, molecular-targeting therapy and immunotherapy. Jpn J Clin Oncol 2019,49(5),412-420","journal-title":"Jpn J Clin Oncol"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3322\/canjclin.54.1.8","volume":"54","author":"Jemal A.","year":"2004","unstructured":"Jemal A.; Tiwari R.C.; Murray T.; Ghafoor A.; Samuels A.; Ward E.; Feuer E.J.; Thun M.J.; Cancer Statistics, 2004. CA Cancer J Clin 2004,54(1),8-29","journal-title":"CA Cancer J Clin"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s12282-020-01077-0","volume":"27","author":"Matsunuma R.","year":"2020","unstructured":"Matsunuma R.; Watanabe T.; Hozumi Y.; Koizumi K.; Ito Y.; Maruyama S.; Ogura H.; Goto K.; Mori H.; Sawai N.; Shiiya N.; Preoperative concurrent endocrine therapy with chemotherapy in luminal B-like breast cancer. Breast Cancer 2020,27(5),819-827","journal-title":"Breast Cancer"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"7727","DOI":"10.2147\/IJN.S182384","volume":"13","author":"Naseri Z.","year":"2018","unstructured":"Naseri Z.; Kazemi Oskuee R.; Jaafari M.R.; Forouzandeh M.; Exosome-mediated delivery of functionally active miRNA-142-3p inhibitor reduces tumorigenicity of breast cancer in vitro and in vivo. Int J Nanomedicine 2018,13,7727-7747","journal-title":"Int J Nanomedicine"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"ra63","DOI":"10.1126\/scisignal.2005231","volume":"7","author":"Ono M.","year":"2014","unstructured":"Ono M.; Kosaka N.; Tominaga N.; Yoshioka Y.; Takeshita F.; Takahashi R.; Yoshida M.; Tsuda H.; Tamura K.; Ochiya T.; Exosomes from bone marrow mesenchymal stem cells contain a microRNA that promotes dormancy in metastatic breast cancer cells. Sci Signal 2014,7(332),ra63","journal-title":"Sci Signal"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1080\/01635581.2019.1616100","volume":"72","author":"Misir S.","year":"2020","unstructured":"Misir S.; Aliyazicioglu Y.; Demir S.; Turan I.; Hepokur C.; Effect of Turkish Propolis on miRNA expression, cell cycle, and apoptosis in human breast cancer (MCF-7) cells. Nutr Cancer 2020,72(1),133-145","journal-title":"Nutr Cancer"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.2174\/1389201019666181112103204","volume":"19","author":"Mavrogiannis A.V.","year":"2019","unstructured":"Mavrogiannis A.V.; Kokkinopoulou I.; Kontos C.K.; Sideris D.C.; Effect of vinca alkaloids on the expression levels of microRNAs targeting apoptosis-related genes in breast cancer cell lines. Curr Pharm Biotechnol 2019,19(13),1076-1086","journal-title":"Curr Pharm Biotechnol"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"110341","DOI":"10.1016\/j.ygeno.2022.110341","volume":"114","author":"Zhang Y.","year":"2022","unstructured":"Zhang Y.; Lai X.; Yue Q.; Cao F.; Zhang Y.; Sun Y.; Tian J.; Lu Y.; He L.; Bai J.; Wei Y.; Bone marrow mesenchymal stem cells-derived exosomal microRNA-16-5p restrains epithelial-mesenchymal transition in breast cancer cells via EPHA1\/NF-\u03baB signaling axis. Genomics 2022,114(3),110341","journal-title":"Genomics"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.bbrc.2004.04.102","volume":"318","author":"Fox B.P.","year":"2004","unstructured":"Fox B.P.; Kandpal R.P.; Invasiveness of breast carcinoma cells and transcript profile: Eph receptors and ephrin ligands as molecular markers of potential diagnostic and prognostic application. Biochem Biophys Res Commun 2004,318(4),882-892","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3322\/caac.20107","volume":"61","author":"Jemal A.","year":"2011","unstructured":"Jemal A.; Bray F.; Center M.M.; Ferlay J.; Ward E.; Forman D.; Global cancer statistics. CA Cancer J Clin 2011,61(2),69-90","journal-title":"CA Cancer J Clin"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s41391-020-0227-1","volume":"24","author":"Jiang C.","year":"2021","unstructured":"Jiang C.; Fedewa S.A.; Wen Y.; Jemal A.; Han X.; Shared decision making and prostate-specific antigen based prostate cancer screening following the 2018 update of USPSTF screening guideline. Prostate Cancer Prostatic Dis 2021,24(1),77-80","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"ref=67","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1002\/tcr.202000104","volume":"21","author":"Tiburcius S.","year":"2021","unstructured":"Tiburcius S.; Krishnan K.; Yang J.H.; Hashemi F.; Singh G.; Radhakrishnan D.; Trinh H.T.; Verrills N.M.; Karakoti A.; Vinu A.; Silica-based nanoparticles as drug delivery vehicles for prostate cancer treatment. Chem Rec 2021,21(6),1535-1568","journal-title":"Chem Rec"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"220","DOI":"10.3322\/caac.21149","volume":"62","author":"Siegel R.","year":"2012","unstructured":"Siegel R.; DeSantis C.; Virgo K.; Stein K.; Mariotto A.; Smith T.; Cooper D.; Gansler T.; Lerro C.; Fedewa S.; Lin C.; Leach C.; Cannady R.S.; Cho H.; Scoppa S.; Hachey M.; Kirch R.; Jemal A.; Ward E.; Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 2012,62(4),220-241","journal-title":"CA Cancer J Clin"},{"key":"ref=69","first-page":"243","volume":"1835","author":"Lisle J.E.","year":"2013","unstructured":"Lisle J.E.; Mertens-Walker I.; Rutkowski R.; Herington A.C.; Stephenson S.A.; Eph receptors and their ligands: Promising molecular biomarkers and therapeutic targets in prostate cancer. Biochim Biophys Acta 2013,1835(2),243-257","journal-title":"Biochim Biophys Acta"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"279","DOI":"10.2147\/OPTH.S89591","volume":"11","author":"Krantz B.A.","year":"2017","unstructured":"Krantz B.A.; Dave N.; Komatsubara K.M.; Marr B.P.; Carvajal R.D.; Uveal melanoma: Epidemiology, etiology, and treatment of primary disease. Clin Ophthalmol 2017,11,279-289","journal-title":"Clin Ophthalmol"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"4651","DOI":"10.1167\/iovs.03-0538","volume":"44","author":"Kujala E.","year":"2003","unstructured":"Kujala E.; Ma\u00a8kitie T.; Kivela\u00a8 T.; Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci 2003,44(11),4651-4659","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1021\/jm201743s","volume":"55","author":"Wang S.","year":"2012","unstructured":"Wang S.; Placzek W.J.; Stebbins J.L.; Mitra S.; Noberini R.; Koolpe M.; Zhang Z.; Dahl R.; Pasquale E.B.; Pellecchia M.; Novel targeted system to deliver chemotherapeutic drugs to EphA2-expressing cancer cells. J Med Chem 2012,55(5),2427-2436","journal-title":"J Med Chem"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/nrc2806","volume":"10","author":"Pasquale E.B.","year":"2010","unstructured":"Pasquale E.B.; Eph receptors and ephrins in cancer: Bidirectional signalling and beyond. Nat Rev Cancer 2010,10(3),165-180","journal-title":"Nat Rev Cancer"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"e24426","DOI":"10.1371\/journal.pone.0024426","volume":"6","author":"Brantley-Sieders D.M.","year":"2011","unstructured":"Brantley-Sieders D.M.; Jiang A.; Sarma K.; Badu-Nkansah A.; Walter D.L.; Shyr Y.; Chen J.; Eph\/ephrin profiling in human breast cancer reveals significant associations between expression level and clinical outcome. PLoS One 2011,6(9),e24426","journal-title":"PLoS One"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"8593","DOI":"10.3390\/ijms22168593","volume":"22","author":"Sahoo A.R.","year":"2021","unstructured":"Sahoo A.R.; Buck M.; Structural and functional insights into the transmembrane domain association of Eph receptors. Int J Mol Sci 2021,22(16),8593","journal-title":"Int J Mol Sci"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867329666220820125638","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/207805\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867329666220820125638","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T16:25:18Z","timestamp":1693671918000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/207805\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":75,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929867329666220820125638","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-02-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-03","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}